Cargando…

Judicious Use of Lipid Lowering Agents in the Management of NAFLD

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world. NAFLD encompasses a spectrum of histological features, including steatosis, steatohepatitis with balloon degeneration, and hepatic fibrosis leading to cirrhosis. In patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Iqbal, Umair, Perumpail, Brandon J., John, Nimy, Sallam, Sandy, Shah, Neha D., Kwong, Waiyee, Cholankeril, George, Kim, Donghee, Ahmed, Aijaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313319/
https://www.ncbi.nlm.nih.gov/pubmed/30249980
http://dx.doi.org/10.3390/diseases6040087
_version_ 1783383904913195008
author Iqbal, Umair
Perumpail, Brandon J.
John, Nimy
Sallam, Sandy
Shah, Neha D.
Kwong, Waiyee
Cholankeril, George
Kim, Donghee
Ahmed, Aijaz
author_facet Iqbal, Umair
Perumpail, Brandon J.
John, Nimy
Sallam, Sandy
Shah, Neha D.
Kwong, Waiyee
Cholankeril, George
Kim, Donghee
Ahmed, Aijaz
author_sort Iqbal, Umair
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world. NAFLD encompasses a spectrum of histological features, including steatosis, steatohepatitis with balloon degeneration, and hepatic fibrosis leading to cirrhosis. In patients with advanced liver damage, NAFLD is associated with an increased risk of hepatocellular carcinoma. Diabetes mellitus, hypertension, and dyslipidemia are components of metabolic syndrome and are commonly associated with NAFLD. Cardiovascular disease is the leading cause of mortality in patients with NAFLD. Therefore, it is important to pre-emptively identify and proactively treat conditions like hyperlipidemia in an effort to favorably modify the risk factors associated with cardiovascular events in patients with NAFLD. The management of hyperlipidemia has been shown to reduce cardiovascular mortality and improve histological damage/biochemical abnormalities associated with non-alcoholic steatohepatitis (NASH), a subset of NAFLD with advance liver damage. There are no formal guidelines available regarding the use of anti-hyperlipidemic drugs, as prospective data are lacking. The focus of this article is to discuss the utility of lipid-lowering drugs in patients with NAFLD.
format Online
Article
Text
id pubmed-6313319
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63133192019-01-04 Judicious Use of Lipid Lowering Agents in the Management of NAFLD Iqbal, Umair Perumpail, Brandon J. John, Nimy Sallam, Sandy Shah, Neha D. Kwong, Waiyee Cholankeril, George Kim, Donghee Ahmed, Aijaz Diseases Review Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world. NAFLD encompasses a spectrum of histological features, including steatosis, steatohepatitis with balloon degeneration, and hepatic fibrosis leading to cirrhosis. In patients with advanced liver damage, NAFLD is associated with an increased risk of hepatocellular carcinoma. Diabetes mellitus, hypertension, and dyslipidemia are components of metabolic syndrome and are commonly associated with NAFLD. Cardiovascular disease is the leading cause of mortality in patients with NAFLD. Therefore, it is important to pre-emptively identify and proactively treat conditions like hyperlipidemia in an effort to favorably modify the risk factors associated with cardiovascular events in patients with NAFLD. The management of hyperlipidemia has been shown to reduce cardiovascular mortality and improve histological damage/biochemical abnormalities associated with non-alcoholic steatohepatitis (NASH), a subset of NAFLD with advance liver damage. There are no formal guidelines available regarding the use of anti-hyperlipidemic drugs, as prospective data are lacking. The focus of this article is to discuss the utility of lipid-lowering drugs in patients with NAFLD. MDPI 2018-09-24 /pmc/articles/PMC6313319/ /pubmed/30249980 http://dx.doi.org/10.3390/diseases6040087 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Iqbal, Umair
Perumpail, Brandon J.
John, Nimy
Sallam, Sandy
Shah, Neha D.
Kwong, Waiyee
Cholankeril, George
Kim, Donghee
Ahmed, Aijaz
Judicious Use of Lipid Lowering Agents in the Management of NAFLD
title Judicious Use of Lipid Lowering Agents in the Management of NAFLD
title_full Judicious Use of Lipid Lowering Agents in the Management of NAFLD
title_fullStr Judicious Use of Lipid Lowering Agents in the Management of NAFLD
title_full_unstemmed Judicious Use of Lipid Lowering Agents in the Management of NAFLD
title_short Judicious Use of Lipid Lowering Agents in the Management of NAFLD
title_sort judicious use of lipid lowering agents in the management of nafld
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313319/
https://www.ncbi.nlm.nih.gov/pubmed/30249980
http://dx.doi.org/10.3390/diseases6040087
work_keys_str_mv AT iqbalumair judicioususeoflipidloweringagentsinthemanagementofnafld
AT perumpailbrandonj judicioususeoflipidloweringagentsinthemanagementofnafld
AT johnnimy judicioususeoflipidloweringagentsinthemanagementofnafld
AT sallamsandy judicioususeoflipidloweringagentsinthemanagementofnafld
AT shahnehad judicioususeoflipidloweringagentsinthemanagementofnafld
AT kwongwaiyee judicioususeoflipidloweringagentsinthemanagementofnafld
AT cholankerilgeorge judicioususeoflipidloweringagentsinthemanagementofnafld
AT kimdonghee judicioususeoflipidloweringagentsinthemanagementofnafld
AT ahmedaijaz judicioususeoflipidloweringagentsinthemanagementofnafld